{
    "clinical_study": {
        "@rank": "75438", 
        "acronym": "CAPS2", 
        "arm_group": [
            {
                "arm_group_label": "Low carbohydrate, lifestyle counseling", 
                "arm_group_type": "Active Comparator", 
                "description": "The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (<20 grams per day) for 6 months."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "The control arm will receive no dietary intervention."
            }
        ], 
        "brief_summary": {
            "textblock": "No treatments have been shown to slow prostate cancer progression after radical\n      prostatectomy. We hypothesize that a carbohydrate restricted diet will slow prostate cancer\n      growth. A total of 60 men with a rising prostate-specific antigen (PSA) after failed primary\n      treatment will be recruited and randomized to either a low-carbohydrate diet (<20 grams\n      carbohydrates/day) or a no-diet control (standard of care) for 6 months. The primary outcome\n      is PSA doubling time."
        }, 
        "brief_title": "Carbohydrate Restriction and Prostate Cancer Growth", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Received prior radical prostatectomy or definitive local radiation for prostate\n             cancer (either external beam radiation, brachytherapy, or combination)\n\n          -  PSA within the past 3 months is between 3 and 10 ng/ml\n\n          -  PSA doubling time (PSADT) >3 months and <24 months\n\n               1. Calculated based at least 2 values in the prior 2 years with the   first  and\n                  last PSA separated by at least 3 months\n\n               2. Use all values in the last 2 years to calculate PSADT\n\n               3. PSADT calculated while NOT on hormonal therapy\n\n               4. If prior hormonal therapy use, then documented normal testosterone is required\n                  before starting to calculate PSADT\n\n          -  BMI >25 kg/m2\n\n          -  Willing to be randomized to a no-diet control or a low-carbohydrate diet\n\n          -  Reads, writes, and understands English\n\n        Exclusion Criteria:\n\n          -  Anticipate needing secondary prostate cancer therapy within the next 6 months (i.e.\n             radiation, or hormonal therapy)\n\n          -  Current use of weight loss medications including herbal weight loss supplements or\n             enrolled in a diet/weight loss program\n\n          -  Currently on therapy aimed at altering testosterone levels (includes\n             gonadotropin-releasing hormone (GnRH) agonist/antagonist, prior bilateral\n             orchiectomy, oral anti-androgens, or 5-alpha reductase inhibitors)\n\n          -  Known distant metastatic disease\n\n          -  Already consuming a carbohydrate-restricted or vegetarian diet\n\n          -  Unable or unwilling to adhere to a carbohydrate-restricted dietary intervention\n\n          -  Weight loss >5% of body weight in the last 6 months\n\n          -  Medical comorbidities that in the opinion of the investigator limits the patient's\n             ability to complete this study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763944", 
            "org_study_id": "Pro00041857", 
            "secondary_id": "1K24CA160653-01A1"
        }, 
        "intervention": {
            "arm_group_label": "Low carbohydrate, lifestyle counseling", 
            "description": "The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.", 
            "intervention_name": "Low carbohydrate diet", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diet", 
            "prostate cancer", 
            "carbohydrate", 
            "lifestyle"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "contact": {
                "email": "jordan.smith@dm.duke.edu", 
                "last_name": "Jordan Smith, RD", 
                "phone": "919-660-6719"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27702"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Pao-Hwa Lin, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men With A Rising PSA After Failed Primary Therapy for Prostate Cancer", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Pao-Hwa Lin", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PSA doubling time will be estimated from PSA measured at baseline, 3 and 6 months post randomization.", 
            "measure": "PSA doubling time (change in PSA over time)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 3 and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763944"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institutes of Health (NIH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}